IP Library Granted Patent US 7,335,181
Granted Patent B2
US 7,335,181 · App. 11/107,618 · Granted Feb 26, 2008

Nitric oxide decontamination of the upper respiratory tract

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,335,181
App. No.
11/107,618
Granted
Feb 26, 2008
Kind
B2
Abstract

A method of topically treating the respiratory tract of a mammal with nitric oxide exposure includes the steps of providing a source of nitric oxide containing gas and delivering the nitric oxide containing gas nasally to the upper respiratory tract of the mammal. Also provided are several designs for a nasal delivery device for the controlled nasal deliver the nitric oxide containing gas.

Claims (25)

1. A method of topically treating infection in the respiratory tract of a mammal, comprising the steps of:

providing a source of nitric oxide containing gas; and

nasally delivering the nitric oxide containing gas, wherein the nitric oxide containing gas is confined to an upper respiratory tract of the mammal.

2. The method of claim 1 , wherein the nitric oxide containing gas is delivered in a volume substantially equal to a volume of gas that would fill the upper respiratory tract of the mammal.

3. The method of claim 2 , wherein the nitric oxide containing gas is delivered from a collapsible reservoir with a volume equal to the volume that would fill the upper respiratory tract of the mammal.

4. The method of claim 1 , wherein the step of nasal delivery is further comprised of:

monitoring an inspiration flow profile of a mammal nasally breathing from a source of breathable gas; and

adding the nitric oxide containing gas to a gas stream flowing from the source of the breathable gas close to the end of the mammal's inspiratory flow.

5. The method of claim 4 , wherein the nitric oxide containing gas is added at a time when the mammal's inspiratory flow is decelerating.

6. The method of claim 4 , wherein the time is after the mammal's inspiratory flow reaches a maximum and returns close to zero flow.

7. The method of claim 1 , wherein the step of nasal delivery is further comprised of:

monitoring an inspiration flow profile of a mammal nasally breathing from a source of breathable gas;

modeling the mammal's inspiration flow profiles for a number of previous breaths; and

adding the nitric oxide containing gas to the gas stream flowing from the source of the breathable gas on a subsequent breath based upon a predicted timing determined from the modeling of the mammal's previous breaths.

8. The method of claim 1 , wherein the step of nasal delivery is further comprised of:

monitoring the volume of breathable gas inspired by the mammal nasally from a source of breathable gas, and

adding the nitric oxide containing to a gas stream flowing from the source of the breathable gas once a predetermined volume of the breathable gas is reached.

9. The method of claim 8 , wherein the predetermined volume of the breathable gas ranges from about 20 mL to 50 mL less than the mammal's tidal volume.

10. The method of claim 1 , further comprising the step of monitoring the pressure in the oral cavity of the mammal.

11. The method of claim 10 , wherein the nitric oxide containing gas is nasally delivered when the pressure in the oral cavity reaches a threshold pressure sufficient to close the soft palate of the mammal.

12. The method of claim 11 , wherein the threshold pressure is in the range of about 5 cm H2O to about 10 cm H2O.

13. The method of claim 10 , wherein the nitric oxide containing gas is nasally delivered at a flow rate of about 1 liter per minute.

14. The method of claim 10 , wherein the nitric oxide containing gas is delivered through a first nostril of the mammal while the other nostril is blocked with a one-way flow valve.

15. The method of claim 1 , wherein the infection of the respiratory tract is due to microorganisms selected from the group consisting of bacteria, mycobateria, virus, parasites and fungi.

16. The method of claim 1 , wherein a concentration of the nitric oxide containing gas confined in the upper respiratory tract ranges from about 150 ppm to about 400 ppm.

Assignments (11)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2025
From: SENSORMEDICS CORPORATION
To: ZOLL MEDICAL CORPORATION
Reel/Frame 072869/0633 →
SECURITY INTEREST Recorded May 9, 2019
From: SENSORMEDICS CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 049126/0905 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2018
From: AIT THERAPEUTICS, INC.
To: ADVANCED INHALATION THERAPIES (AIT) LTD.
Reel/Frame 047562/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2018
From: ADVANCED INHALATION THERAPIES (AIT) LTD.
To: AIT THERAPEUTICS, INC.
Reel/Frame 046234/0061 →
FIRST LIEN SECURITY AGREEMENT Recorded Apr 18, 2018
From: SENSORMEDICS CORPORATION
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 045968/0865 →
SECOND LIEN SECURITY AGREEMENT Recorded Apr 18, 2018
From: SENSORMEDICS CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 045782/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2017
From: PULMONOX TECHNOLOGIES CORPORATION
To: ADVANCED INHALATION THERAPIES (AIT) LTD.
Reel/Frame 043779/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2007
From: STENZLER, ALEX
To: SENSORMEDICS CORPORATION
Reel/Frame 020137/0496 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2007
From: MILLER, CHRISTOPHER C.
To: PULMONOX TECHNOLOGIES CORPORATION
Reel/Frame 020137/0492 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2006
From: MILLER, CHRISTOPHER C.
To: PULMONOX TECHNOLOGIES CORPORATION
Reel/Frame 017740/0825 →
SECURITY INTEREST Recorded Apr 7, 2006
From: THERANOX, INC.
To: VIASYS HOLDINGS INC.
Reel/Frame 017435/0358 →